Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal
FREMONT, Calif. , Feb. 21, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb.
Ardelyx to Receive a $5 Million Milestone Payment Company Narrows Timeline for its PHREEDOM trial and announces AMPLIFY, a new Phase 3 Trial evaluating tenapanor in combination with binders FREMONT, Calif. , Feb. 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) ( Ardelyx ) today announced that
FREMONT, Calif. , Nov. 13, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018 .
Company Plans to Commence a Phase 2/3 Clinical Study Evaluating Tenapanor in Combination with Phosphate Binders FREMONT, Calif. , Oct. 26, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in
FREMONT, Calif. , Oct. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology
FREMONT, Calif. , Oct. 4, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018 , from 8 to 10 a.m. ET in New York City . This year's event is the first of an anticipated annual series of events, and will
FREMONT, Calif. , Sept. 13, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) requesting U.S. marketing authorization of tenapanor for the treatment of patients with irritable bowel
FREMONT, Calif. , Aug. 29, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine .